Agios Pharmaceuticals (AGIO) Change in Acquisitions & Divestments (2012 - 2026)

Agios Pharmaceuticals has reported Change in Acquisitions & Divestments for 15 years, with the latest figure at $290.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 0.7% year-over-year to $290.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 40.3% YoY), and the FY2025 full-year result was $1.0 billion, up 26.26% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $290.3 million, up from $252.3 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $368.7 million in Q1 2024, with the low at $141.9 million in Q2 2024.
• Historically, Change in Acquisitions & Divestments has averaged $233.1 million across 5 years, with a median of $220.6 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments jumped 147.84% — and 2023, when it sank 55.06%.
• Agios Pharmaceuticals' Change in Acquisitions & Divestments stood at $198.9 million in 2022, then retreated by 6.38% to $186.2 million in 2023, then slipped by 19.36% to $150.1 million in 2024, then soared by 68.03% to $252.3 million in 2025, then advanced by 15.06% to $290.3 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $290.3 million (Q1 2026), $252.3 million (Q4 2025), and $272.1 million (Q3 2025), per Business Quant data.